Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3334)
All Articles published online
|
Feb 14, 2009 (publication date) through Dec 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Edeline J, Raoul JL, Vauleon E, Guillygomac’h A, Boudjema K, Boucher E. Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: A retrospective study. World J Gastroenterol 2009; 15(6): 713-716 [PMID: 19222095 DOI: 10.3748/wjg.15.713] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v15/i6/713.htm |
| Number | Citing Articles |
| 1 |
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology 2012; 56(4): 908 doi: 10.1016/j.jhep.2011.12.001
|
| 2 |
Govindarajan Narayanan, Yilun Koethe, Nicole Gentile. Irreversible Electroporation of the Hepatobiliary System: Current Utilization and Future Avenues. Medicina 2024; 60(2): 251 doi: 10.3390/medicina60020251
|
| 3 |
GEN-SHEN ZHONG, MIN-NA WU, XIAO-FANG GUO, SHENG-HUA ZHANG, QING-FANG MIAO, YONG-SU ZHEN. Antitumor activities of dFv-LDP-AE: An enediyne-energized fusion protein targeting tumor-associated antigen gelatinases. Oncology Reports 2012; 28(4): 1193 doi: 10.3892/or.2012.1910
|
| 4 |
Omar Abdel-Rahman. Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside. Journal of the Egyptian National Cancer Institute 2013; 25(4): 165 doi: 10.1016/j.jnci.2013.08.002
|
| 5 |
B. Alkofer, V. Lepennec, L. Chiche. Hepatocellular cancer in the non-cirrhotic liver. Journal of Visceral Surgery 2011; 148(1): 3 doi: 10.1016/j.jviscsurg.2010.12.012
|
| 6 |
B. Alkofer, V. Lepennec, L. Chiche. Hépatocarcinome sur foie non cirrhotique. Journal de Chirurgie Viscérale 2011; 148(1): 3 doi: 10.1016/j.jchirv.2010.12.015
|
| 7 |
Qiaomiao Lu, Yu Long, Yongkang Gai, Qingyao Liu, Dawei Jiang, Xiaoli Lan. [177Lu]Lu-PSMA-617 theranostic probe for hepatocellular carcinoma imaging and therapy. European Journal of Nuclear Medicine and Molecular Imaging 2023; 50(8): 2342 doi: 10.1007/s00259-023-06155-x
|
| 8 |
Aly M. Azmy, Khalid E. Nasr, Nagy S. Gobran, M. Yassin. Gemcitabine Plus Carboplatin in Patients with Advanced Hepatocellular Carcinoma: Results of a Phase II Study. ISRN Oncology 2012; 2012: 1 doi: 10.5402/2012/420931
|
| 9 |
Peter R. Galle, Alejandro Forner, Josep M. Llovet, Vincenzo Mazzaferro, Fabio Piscaglia, Jean-Luc Raoul, Peter Schirmacher, Valérie Vilgrain. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology 2018; 69(1): 182 doi: 10.1016/j.jhep.2018.03.019
|
| 10 |
Franco Trevisani, Marta Frigerio, Valentina Santi, Alice Grignaschi, Mauro Bernardi. Hepatocellular carcinoma in non-cirrhotic liver: A reappraisal. Digestive and Liver Disease 2010; 42(5): 341 doi: 10.1016/j.dld.2009.09.002
|
| 11 |
Mélissa Léveillé, Jennifer L. Estall. Mitochondrial Dysfunction in the Transition from NASH to HCC. Metabolites 2019; 9(10): 233 doi: 10.3390/metabo9100233
|
| 12 |
Brian A. Boone, David L. Bartlett, Amer H. Zureikat. Isolated Hepatic Perfusion for the Treatment of Liver Metastases. Current Problems in Cancer 2012; 36(2): 27 doi: 10.1016/j.currproblcancer.2011.12.001
|
| 13 |
Lorenza Rimassa, Armando Santoro. The present and the future landscape of treatment of advanced hepatocellular carcinoma. Digestive and Liver Disease 2010; 42: S273 doi: 10.1016/S1590-8658(10)60516-6
|
| 14 |
Jinming Zhang, Yifeng Zheng, Xi Xie, Lan Wang, Ziren Su, Yitao Wang, Kam W. Leong, Meiwan Chen. Cleavable Multifunctional Targeting Mixed Micelles with Sequential pH-Triggered TAT Peptide Activation for Improved Antihepatocellular Carcinoma Efficacy. Molecular Pharmaceutics 2017; 14(11): 3644 doi: 10.1021/acs.molpharmaceut.7b00404
|
| 15 |
Hiroki Nishikawa, Toru Kimura, Ryuichi Kita, Yukio Osaki. Radiofrequency ablation for hepatocellular carcinoma. International Journal of Hyperthermia 2013; 29(6): 558 doi: 10.3109/02656736.2013.821528
|
| 16 |
Conventional Oral Systemic Chemotherapy for Postoperative Hepatocellular Carcinoma. Journal of Cancer Research Updates 2014; 3(1): 11 doi: 10.6000/1929-2279.2014.03.01.2
|
| 17 |
Vladimir M. Subbotin. Privileged portal metastasis of hepatocellular carcinoma in light of co-evolution of a visceral portal system and the liver in the chordate lineage: a search for therapeutic targets. Drug Discovery Today 2018; 23(3): 548 doi: 10.1016/j.drudis.2018.01.020
|
| 18 |
Aldo Parodi Pita. Factores epidemiológicos relacionados al Carcinoma Hepatocelular.. Oncología (Ecuador) 2017; : 115 doi: 10.33821/195
|
| 19 |
JIANHONG ZHONG, BANGDE XIANG, LIANG MA, LEQUN LI. Conventional oral systemic chemotherapy for postoperative hepatocellular carcinoma: A systematic review. Molecular and Clinical Oncology 2014; 2(6): 1091 doi: 10.3892/mco.2014.337
|
| 20 |
|
| 21 |
Hiroki Nishikawa, Yukio Osaki, Ryuichi Kita, Toru Kimura. Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma in Japan. Cancers 2012; 4(1): 165 doi: 10.3390/cancers4010165
|
| 22 |
Qin Liu, Rutian Li, Zhenshu Zhu, Xiaoping Qian, Wenxian Guan, Lixia Yu, Mi Yang, Xiqun Jiang, Baorui Liu. Enhanced antitumor efficacy, biodistribution and penetration of docetaxel-loaded biodegradable nanoparticles. International Journal of Pharmaceutics 2012; 430(1-2): 350 doi: 10.1016/j.ijpharm.2012.04.008
|
| 23 |
Vladimir M. Subbotin. A hypothesis on paradoxical privileged portal vein metastasis of hepatocellular carcinoma. Can organ evolution shed light on patterns of human pathology, and vice versa?. Medical Hypotheses 2019; 126: 109 doi: 10.1016/j.mehy.2019.03.019
|
| 24 |
Marcus A. Wörns, Timon Bosslet, Anja Victor, Sandra Koch, Maria Hoppe-Lotichius, Michael Heise, Torsten Hansen, Michael B. Pitton, Ina M. Niederle, Marcus Schuchmann, Arndt Weinmann, Christoph Düber, Peter R. Galle, Gerd Otto. Prognostic factors and outcomes of patients with hepatocellular carcinoma in non-cirrhotic liver. Scandinavian Journal of Gastroenterology 2012; 47(6): 718 doi: 10.3109/00365521.2012.677952
|
| 25 |
Alejandro Forner, Marine Gilabert, Jordi Bruix, Jean-Luc Raoul. Treatment of intermediate-stage hepatocellular carcinoma. Nature Reviews Clinical Oncology 2014; 11(9): 525 doi: 10.1038/nrclinonc.2014.122
|
| 26 |
Aakash Desai, Sonia Sandhu, Jin-Ping Lai, Dalbir Singh Sandhu. Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review. World Journal of Hepatology 2019; 11(1): 1-18 doi: 10.4254/wjh.v11.i1.1
|
| 27 |
Xiang-yu Zhong, Xiao-xue Xu, Jian-hua Yu, Gui-xing Jiang, Yang Yu, Sheng Tai, Zhi-dong Wang, Yun-fu Cui. Clinical and biological significance of Cdk10 in hepatocellular carcinoma. Gene 2012; 498(1): 68 doi: 10.1016/j.gene.2012.01.022
|
| 28 |
Seung Min Jung, Jeong Won Jang, Chan Ran You, Sun Hong Yoo, Jung Hyun Kwon, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Kyu Won Chung, Chul Seung Kay, Hyun Suk Jung. Role of intrahepatic tumor control in the prognosis of patients with hepatocellular carcinoma and extrahepatic metastases. Journal of Gastroenterology and Hepatology 2012; 27(4): 684 doi: 10.1111/j.1440-1746.2011.06917.x
|
| 29 |
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. European Journal of Cancer 2012; 48(5): 599 doi: 10.1016/j.ejca.2011.12.021
|
| 30 |
V. V. Breder, K. K. Laktionov, M. I. Davydov. PHARMACOLOGICAL THERAPY OF HEPATOCELLULAR CANCER PRACTICAL ISSUES AND SOLUTIONS. Medical Council 2017; (14): 11 doi: 10.21518/2079-701X-2017-14-11-23
|
| 31 |
Jirapat Wonglhow, Patrapim Sunpaweravong, Chirawadee Sathitruangsak, Arunee Dechaphunkul. LABS score– a prognostic tool for FOLFOX4-treated advanced hepatocellular carcinoma and real-world efficacy: a single-center retrospective study. BMC Cancer 2024; 24(1) doi: 10.1186/s12885-024-12040-z
|
| 32 |
Ivonete Sandra de Souza e Silva, Adriano Miziara Gonzáles, Marcelo Moura Linhares, Alcides Salzedas Neto, Denis Szejnfeld, Giuseppe D'Ippolito, Gaspar de Jesus Lopes Filho, Valeria Pereira Lanzoni, Carla Adriana Matos. Long-term follow-up after resection of thyroid metastases from hepatocellular carcinoma in noncirrhotic liver. Arquivos Brasileiros de Endocrinologia & Metabologia 2013; 57(4): 327 doi: 10.1590/S0004-27302013000400009
|
| 33 |
Jaleh Varshosaz, Farshid Hassanzadeh, Hojjat Sadeghi, Zahra Ghelich Khan, Mahboobeh Rostami, Mohamed Bououdina. Retinoic Acid Decorated Albumin‐Chitosan Nanoparticles for Targeted Delivery of Doxorubicin Hydrochloride in Hepatocellular Carcinoma. Journal of Nanomaterials 2013; 2013(1) doi: 10.1155/2013/254127
|
| 34 |
Julien Edeline, Eveline Boucher, Yan Rolland, Elodie Vauléon, Marc Pracht, Christophe Perrin, Catherine Le Roux, Jean‐Luc Raoul. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2012; 118(1): 147 doi: 10.1002/cncr.26255
|
| 35 |
Hoi-Hung Chan, Tian-Huei Chu, Hsin-Fan Chien, Cheuk-Kwan Sun, E-Ming Wang, Huay-Ben Pan, Hsiao-Mei Kuo, Tsung-Hui Hu, Kwok-Hung Lai, Jiin-Tsuey Cheng, Ming-Hong Tai. Rapid induction of orthotopic hepatocellular carcinoma in immune-competent rats by non-invasive ultrasound-guided cells implantation. BMC Gastroenterology 2010; 10(1) doi: 10.1186/1471-230X-10-83
|
| 36 |
Jirapat Wonglhow, Patrapim Sunpaweravong, Chirawadee Sathitruangsak, Arunee Dechaphunkul. The Performance of a Survival Nomogram and Albumin–Bilirubin Grade as Prognostic Tools in Advanced Hepatocellular Carcinoma Treated with FOLFOX4. Journal of Personalized Medicine 2024; 14(4): 403 doi: 10.3390/jpm14040403
|
| 37 |
Mengchao Wu, Feng Shen, Jiamei Yang, Weiping Zhou, Yiqun Yan, Xiaohui Fu. Primary Liver Cancer. 2012; : 399 doi: 10.1007/978-3-642-28702-2_13
|